You are here: Industry Insights > Merck

News List

ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) prnasia
March 02, 2020
CHANGE II is the first Phase III trial in the Chinese population to prospectively evaluate an anti-epidermal growth factor receptor (EGFR) antibody in the first-line treatment of patients with R/M SCCHN.
Merck closes $2.7bn acquisition of biopharmaceutical firm ArQule pharmaceutical-technology
January 19, 2020
Merck (MSD) has completed its previously announced acquisition of US-based biopharmaceutical company ArQule. The $2.7bn deal closed following completion of the cash tender offer that involved acquiring ArQule’s outstanding shares of common stock at $20 pe
BioMed X Starts New Research Program in Autoimmune Diseases with Merck b3cnewswire
January 17, 2020
BioMed X announced today the start of a new joint research group in collaboration with Merck. With this new group, BioMed X and Merck extend their ongoing collaboration to a total of six joint research projects at the BioMed X Innovation Center in Heidelb
Merck collaborates on small molecule inhibitors with Taiho and Astex pharmaceutical-technology
January 09, 2020
Merck has signed an exclusive worldwide research collaboration and licence agreement with two Otsuka Pharmaceutical subsidiaries, Japanese Taiho Pharmaceutical and UK-based Astex Pharmaceuticals.
Three more companies raise their US drug list prices europeanpharmaceuticalreview
January 07, 2020
Novartis, Merck and Allergan have joined numerous other pharmaceutical companies by increasing the price of certain drugs since the start of 2020.
AZ, Merck's Lynparza lands FDA nod in pancreatic cancer fiercepharma
January 03, 2020
Earlier this month, FDA experts voted—barely—that the agency should approve AstraZeneca and Merck’s Lynparza in pancreatic cancer.
Merck secures FDA authorisation for Ebola vaccine Ervebo pharmaceutical-technology
December 23, 2019
Merck (MSD) has received the US Food and Drug Administration (FDA) approval for its Ervebo vaccine to prevent Ebola virus disease (EVD) caused by Zaire ebolavirus.
Merck signs CRISPR Integration Technology licensing agreement with Promega biospectrumasia
December 22, 2019
Under this licensing agreement, Promega plans to use Merck’s intellectual property to develop CRISPR-edited cell lines
How Merck's desire for more 'control' became a $2.7B ArQule buy fiercepharma
December 20, 2019
It’s not uncommon for partnership talks focused on one drug to escalate into a full-on buyout. And that's just what happened with Merck & Co.’s $2.7 billion deal for ArQule.
Is AZ, Merck's Lynparza approvable in pancreatic cancer? fiercepharma
December 17, 2019
When AstraZeneca and Merck & Co. unveiled in February that a study of Lynparza in pancreatic cancer had read out positively, there was much excitement in the oncology world.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page